USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NATURE TECHNOLOGY CORPORATION
Address:
4701 INNOVATION DRIVE
LINCOLN, NE 68521-
Phone:
N/A
URL:
N/A
EIN:
134161210
DUNS:
7588486
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,162,204.00 7
SBIR Phase II $1,740,035.00 2

Award List:

GENE SELF ASSEMBLY TECHNOLOGY

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$139,700.00
Agency:
HHS
Principal Investigator:
Zink, Mary A
Abstract:
N/a

Promoter Rescue Vectors

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$142,017.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Mouse VL30 (retrotransposon) long terminal repeats (LTRs) are a potential source of tissue-specific transcriptional promoters that can be used to deliver and express therapeutic genes in humans. Such vectors are badly needed, because the current retroviral… More

Chimeric enzyme for host nucleic acid autohydrolysis

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$143,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): DNA vaccines and gene medicines are emerging as an important new class of pharmaceuticals that are derived from bacterial plasmids. For use in humans, plasmid DNA should be essentially free from bacterial genomic DNA and RNA, protein and endotoxin. The… More

Antisense inhibitors for enhanced plasmid production

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$136,195.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Large scale manufacture of plasmid DNA is becoming increasingly important as the next generation of biotechnology products (gene medicines and DNA vaccines) make their way into clinical trials, and eventually into the pharmaceutical marketplace. Although… More

Chimeric enzyme for nucleic acid autohydrolysis

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$819,371.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): DNA vaccines and gene medicines, derived from bacterial plasmids, are emerging as an important new class of pharmaceuticals. DNA molecules made strictly by rational design allows the manufacturer to bypass years of development for the production of efficacious… More

eukaryotic expression vectors resistant to transgene silencing

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$145,542.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Eukaryotic expression vectors are utilized for various biomedical applications including protein production, gene therapy and gene vaccination. A key barrier is that expression vectors undergo promoter inactivation (sil encing) over time. This lack of sustained… More

Rapid deployment DNA vaccine for pandemic influenza

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$207,016.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): DNA-only vaccination would significantly enhance the rapid deployment utility of DNA vaccines for pandemic application (development times for DNA vaccines are significantly shorter than those for protein or viral vector systems). The overall goal of this project… More

eukaryotic expression vectors resistant to transgene silencing

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$920,664.00
Agency:
HHS
Principal Investigator:
James Williams – 402-472-6530
Abstract:
DESCRIPTION (provided by applicant): Plasmid-directed gene expression is now near the efficacy barrier that to date has prevented commercialization of plasmid-based therapies for human health applications. Previous innovations such as electroporation (EP)increased transgene expression through more… More

Improving Obesity Outcomes Through Interactive Web-Based Clinical Skills Training

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$247,934.00
Agency:
HHS
Principal Investigator:
James Williams – 402-472-6530
Abstract:
DESCRIPTION (provided by applicant): To commercialize non-viral gene medicines, it is critical that both vector potency (i.e. therapeutic transgene expression levels) and the duration of the therapeutic effect be improved. Potent dose-sparing extended duration gene therapies will have a cost and… More